Design and synthesis of novel mitochondria-targeted CDDO derivatives as potential anti-cancer agents

Area of Science:

• Medicinal Chemistry
• Mitochondrial Biology
• Oncology

Background:

• Oleanolic acid (OA) derivatives, including CDDOs, exhibit potent antitumor activity.
• Current CDDOs lack tumor cell selectivity, leading to significant side effects.
• Tumor cells possess higher mitochondrial membrane potential, a targetable characteristic.

Purpose of the Study:

• To enhance the mitochondrial targeting of CDDO derivatives to improve tumor selectivity.
• To synthesize and evaluate novel CDDO conjugates with phosphine cations (TPP+ or TCP+).

Main Methods:

• Synthesis of TPP+ and TCP+ conjugated CDDO derivatives.
• In vitro evaluation of anti-tumor activity and cellular uptake in cancer cell lines (e.g., MCF-7).
• Assessment of mitochondrial membrane potential, cell cycle progression, and apoptosis induction.

Main Results:

• The TPP+ derivative, compound 5b, demonstrated superior anti-tumor activity and enhanced selectivity compared to CDDO-Me.
• Compound 5b showed increased uptake in cancer cell mitochondria.
• 5b induced mitochondrial membrane potential decline, cell cycle arrest, and apoptosis via the intrinsic pathway.

Conclusions:

• Mitochondrial-targeting strategies can overcome the selectivity limitations of CDDOs.
• Compound 5b represents a promising candidate for improved cancer therapy.
• This approach offers renewed potential for CDDO-based cancer treatments.